Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bruggmann

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Addiction (Abingdon, England)|January 25, 2019
Chronic obstructive pulmonary disease (COPD) among opioid-dependent patients in agonist treatment. A diagnostic studyThomas Grischott, Luis Falcato, Oliver Senn, et al.
Swiss Medical Weekly|July 6, 2023
Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal studyRosario Agosti-Gonzalez, Luis Falcato, Thomas Grischott, et al.
European Addiction Research|December 15, 2015
Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C InfectionMaria Dickson-Spillmann, Severin Haug, Ambros Uchtenhagen, et al.
Swiss Medical Weekly|February 20, 2025
Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance studyRaphael Magnolini, Kuvinda Kossinna, Daniel Bjasch, et al.
Journal of Viral Hepatitis|October 20, 2018
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysisFrançois Girardin, Natalie Hearmon, Francesco Negro, et al.
Swiss Medical Weekly|January 12, 2022
High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional studyPhilip Bruggmann, Oliver Senn, Anja Frei, et al.
The International Journal on Drug Policy|August 10, 2015
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugsJason Grebely, Philip Bruggmann, Carla Treloar, et al.
Harm Reduction Journal|August 21, 2025
Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practiceRaphael Magnolini, Sofia Laura Bottoni, Helena Hammer, et al.
The International Journal on Drug Policy|August 10, 2015
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugsJason Grebely, Philip Bruggmann, Carla Treloar, et al.
The International Journal on Drug Policy|September 11, 2017
Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapyJason Grebely, Julie Bruneau, Philip Bruggmann, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Addiction (Abingdon, England)|January 25, 2019
Chronic obstructive pulmonary disease (COPD) among opioid-dependent patients in agonist treatment. A diagnostic studyThomas Grischott, Luis Falcato, Oliver Senn, et al.
Swiss Medical Weekly|July 6, 2023
Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal studyRosario Agosti-Gonzalez, Luis Falcato, Thomas Grischott, et al.
European Addiction Research|December 15, 2015
Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C InfectionMaria Dickson-Spillmann, Severin Haug, Ambros Uchtenhagen, et al.
Swiss Medical Weekly|February 20, 2025
Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance studyRaphael Magnolini, Kuvinda Kossinna, Daniel Bjasch, et al.
Journal of Viral Hepatitis|October 20, 2018
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysisFrançois Girardin, Natalie Hearmon, Francesco Negro, et al.
Swiss Medical Weekly|January 12, 2022
High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional studyPhilip Bruggmann, Oliver Senn, Anja Frei, et al.
The International Journal on Drug Policy|August 10, 2015
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugsJason Grebely, Philip Bruggmann, Carla Treloar, et al.
Harm Reduction Journal|August 21, 2025
Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practiceRaphael Magnolini, Sofia Laura Bottoni, Helena Hammer, et al.
The International Journal on Drug Policy|August 10, 2015
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugsJason Grebely, Philip Bruggmann, Carla Treloar, et al.
The International Journal on Drug Policy|September 11, 2017
Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapyJason Grebely, Julie Bruneau, Philip Bruggmann, et al.
Pageof 9